Literature DB >> 3897395

Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats.

R Roosendaal, I A Bakker-Woudenberg, J C van den Berg, M F Michel.   

Abstract

An experimental Klebsiella pneumoniae pneumonia in rats was used to study the influence of continuous or of intermittent (8-hr intervals) administration of ceftazidime on therapeutic efficacy. Antimicrobial response was evaluated with respect to the calculated total daily dose that protected 50% of the animals from death (PD50) until 16 days after termination of a four-day treatment. When antibiotic treatment was started 5 hr after bacterial inoculation, the PD50 values after continuous and after intermittent administration of ceftazidime were 0.36 and 1.42 mg/kg per day, respectively (P less than .001). With a delay in the administration of the antibiotic to 34 hr after inoculation, the respective PD50 values were 1.08 and 13.06 mg of ceftazidime/kg per day (P less than .001). These studies show an improved therapeutic efficacy that increased with a delay in treatment when ceftazidime was administered by continuous infusion as compared with administration at 8-hr intervals. Continuous administration of PD50 doses of ceftazidime resulted in serum levels that were constantly below the MIC of the infecting Klebsiella strain.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3897395     DOI: 10.1093/infdis/152.2.373

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.

Authors:  J Berkhout; L G Visser; P J van den Broek; J A M van de Klundert; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 2.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

3.  Pharmacodynamics and alternative antimicrobial dosing regimens.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1995-01

Review 4.  The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations.

Authors:  R Janknegt
Journal:  Pharm World Sci       Date:  1997-06

5.  Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Wil H F Goessens; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Choosing between the new cephalosporin antibiotics: a pharmacodynamic approach.

Authors:  D P Nicolau; R Quintiliani
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

7.  Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo.

Authors:  J Renneberg; M Walder
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

8.  Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

9.  Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.

Authors:  Yigong Ge; David Maynard; Douglas E Rickert
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

10.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.